CAPTURE your learning

Patients can no longer be started on funded selegiline. Patients who were on selegiline prior to 1 August 2021 will need their prescriptions endorsed to receive subsidised supplies. An alternative MAO-B inhibitor, rasagiline, may be a suitable agent for new patients or those transitioning from selegiline.

This resource provides a timeline for the changes and information about transitioning patients from selegiline. Advice on prescribing rasagiline is also included.

Biological medicines are already used in Aotearoa New Zealand and with more being developed internationally, it’s important that you feel comfortable using them. We’ve highlighted five key aspects of these medicines to give you a quick introduction to using biologicals.

From 1 September and when clinically indicated, dulaglutide can be started in adult patients with type 2 diabetes using the steps shown in this resource.

Talking points, relevant for all patients starting dulaglutide, are provided along with two algorithms and accompanying prescribing notes.

In this webinar, Dr Ryan Paul discusses the newly-funded type 2 diabetes medication dulaglutide, and provides advice on when and how to use it.

In this webinar, Dr Raewyn Fisher discusses the range of disease-modifying therapies that have improved heart failure outcomes, and provides reassurance around the funding changes to cilazapril.

When initiating either empagliflozin or dulaglutide, the newly funded second-line type 2 diabetes agents,¹ choice is based primarily on predominant comorbidities, clinical features and tolerability.

Administration route is an additional factor; dulaglutide is a once-weekly, subcutaneous injection and empagliflozin is a daily tablet. Patient factors are also important, and the contraindications and adverse effects profiles differ. 

Read the HAH Bulletin to find out more.